Discovery Life Sciences’ sequencing and bioinformatics laboratory, HudsonAlpha Discovery, accelerates oncology programs by identifying and validating cancer biomarkers in resected tumor tissues using optimized, high coverage next generation sequencing (NGS) services. Our research-use only (RUO) service leverages highly sensitive Illumina TSO500 sequencing assays and includes comprehensive bioinformatics analysis to simplify decision-making. The TSO500 Solid Tumor assay assesses 523 genes for single nucleotide variants (SNVs), insertions/deletions (InDels), copy number variants (CNVs), Tumor Mutation Burden (TMB), and Microsatellite Instability (MSI) as well as 55 RNA gene fusions to provide pan-cancer genomic biomarker evaluation.
Discovery also offers TSO500 ctDNA analysis of plasma specimens and matched biospecimen sets to advance liquid biopsy applications.
